期刊文献+

下咽癌Hep-2v多药耐药细胞株的筛选 被引量:1

Hep-2v Multidrug-Resistance Cell Line selected by Vincristine and its identification
暂未订购
导出
摘要 目的 建立 Hep- 2 v多药耐药 (MDR)细胞株 ,以进一步研究探讨咽喉部肿瘤 MDR特征及其逆转方法。方法 以下咽癌 Hep- 2细胞为亲本细胞 ,用长春新碱 (VCR)进行耐药细胞筛选 ,选择出 Hep- 2 v耐药细胞株。用流式细胞仪测定筛选前后两组表面糖蛋白 P- 1 70的阳性率及细胞内罗丹明蓄积率。以 MTT法测定筛选前后 VCR对两组细胞的细胞生长半数抑制浓度 (IC50 )比较其细胞毒作用。结果 亲本细胞 Hep- 2经 VCR筛选后检测其耐药性状 ,MTT法测得其 VCR的 IC50 由筛选前的 6 0 nmol/ L上升到约 1 2 0 0 nmol/ L ,流式细胞仪检测细胞表面糖蛋白 P-1 70阳性率由亲本细胞的 2 0 %左右增加到 90 %以上。流式细胞仪检测细胞内罗丹明蓄积率从筛选前的平均 76 .2 %降至 2 6 .3%。结论 本研究建立的耐药细胞株 Hep- 2 v主要表现为 mdr1基因介导的 MDR性状 ,其对选择药物 VCR的敏感性明显降低 ,因此 Hep- 2 v细胞株可作为 Objective Establishing Hep 2v Cell Line to study Multidrun Resistance(MDR) and its reversion.Methods Establishment of resistance cell line:The parental cell from pharyngeal cancer exposed to vincristine(VCR)with increasing concentration for four months.The selected cell,termen Hep 2v,was as a subject for this study.Quantitative analysis of P 170 was made by Flow Cytometry(FCM).The drug accumulation in the cells was measured by FCM after Rhodanmin staining,and the cellular toxicity of VCR was determined by MTT method.Results Selected cell with VCR appeared MDR phenotype obviously.The positive rate of P 170 was from about 20% in parental cell Hep 2 up to more than 90% in selected cell Hep 2v.Correspondingly,the drug accumulation in the cells indicated by Rhodamin staining decreased from 76 2% down to 26 3% after stressed by VCR.The IC 50 of VCR was from 60 nmol/L in Hep 2 up to 1200 nmol/L in Hep 2v.Conclusion\ The cell line Hep 2v established in this study revealled the mdrl mediated MDR phenotype.The sensitivity of the cell to VCR was decreased greatly.It is indicated that Hep 2v can be served as a model for the study of MDR.
出处 《福建医药杂志》 CAS 2003年第6期1-3,共3页 Fujian Medical Journal
关键词 下咽癌 Hep-2v细胞 多药耐药 药物敏感性 细胞毒性 长春新碱 化疗 Multi drug resistance Hep 2 cell line Laryngopharyngeal carcinoma
  • 相关文献

参考文献2

  • 1Susan E. Kane,Ira Pastan,Michael M. Gottesman. Genetic basis of multidrug resistance of tumor cells[J] 1990,Journal of Bioenergetics and Biomembranes(4):593~618
  • 2Shin-ichi Akiyama,Antonio Fojo,John A. Hanover,Ira Pastan,Michael M. Gottesman. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs[J] 1985,Somatic Cell and Molecular Genetics(2):117~126

同被引文献11

  • 1Kane SE,Pastan I,Gottesman MM.Genetic basis of drug resistance of tumour cells[J].J Bioeneg Biomem,1990,22:593-596.
  • 2Van der Bliek AM,Borst P.Multidrug resistance[J].Adv Cancer Res,1989,52:165-203.
  • 3Stein CA.How to design an antisense oligodeoxynucleotide experiment:a consensus approach[J].Antisense & Nucleic Acid Drug Development,1998,8:129-132.
  • 4Miller TP,Grogan TM,Dalton WS,et al.P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapmil[J].J Clin Oncol,1991,9:7.
  • 5Hogrefe RI.an Antisense oligonucleotide primer[J].Antisense & Nucleic Acid Development,1999,9:351-357.
  • 6Crooke ST.An overview of progress in antisense therapeutics[J].Antisense & Nucleic Acid Drug Development,1998,8:115-122.
  • 7Rivoltini L,Colombo MP,Supino R,et al.Modulation of multidrug resistance by verapamil or mdr1 antisense oligodeoxynucleotides does not change the high susceptibility to lymphokine-activated kills in mdr-resistant human carcinoma(LoVo) line[J].Int J Cancer,1990,46:727-732.
  • 8Ramachandran C,Wellham LL.Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts[J].Anticancer Res,2003,23:2681-2690.
  • 9Funato T.Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance[J].Methods Mol Med,2004,106:215-234.
  • 10Quattrone A,Papucci L,Morganti M,et al.Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance[J].Oncol Res,1994,6:311-320.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部